Pharmaceutical Opioid Use and Dependence among People Living with Chronic Pain: Associations Observed within the Pain and Opioids in Treatment (POINT) Cohort

Pain Medicine (United States)

Volumn 16, Issue 9, 2015, Pages 1745-1758

  Campbell, Gabrielle ^a   Nielsen, Suzanne ^a   Larance, Briony ^a   Bruno, Raimondo ^b   Mattick, Richard ^a   Hall, Wayne ^c,g   Lintzeris, Nicholas ^d,e   Cohen, Milton ^f   Smith, Kimberley ^a   Degenhardt, Louisa ^a,h,i,j  

^a UNIVERSITY OF NEW SOUTH WALES   (Australia)

^b UNIVERSITY OF TASMANIA   (Australia)

^c UNIVERSITY OF QUEENSLAND   (Australia)

^d UNIVERSITY OF SYDNEY   (Australia)

^e SOUTH EASTERN SYDNEY LOCAL HEALTH DISTRICT   (Australia)

^f ST VINCENT'S CLINIC   (Australia)

^g KING'S COLLEGE LONDON   (United Kingdom)

^h UNIVERSITY OF MELBOURNE   (Australia)

ⁱ MURDOCH CHILDREN'S RESEARCH INSTITUTE   (Australia)

^j UNIVERSITY OF WASHINGTON   (United States)

more..

Author keywords

Chronic Pain; Dependence; Opioids

Indexed keywords

MORPHINE; OPIATE; OXYCODONE; NARCOTIC ANALGESIC AGENT;

ADULT; AGE DISTRIBUTION; ANXIETY; ARTICLE; AUSTRALIA; CHRONIC PAIN; DEPRESSION; DISEASE SEVERITY; DRUG USE; EMPLOYMENT STATUS; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; OPIATE ADDICTION; POSTTRAUMATIC STRESS DISORDER; PRESCRIPTION; PREVALENCE; RISK FACTOR; SCORING SYSTEM; SEX RATIO; SUBSTANCE ABUSE; ADOLESCENT; AGED; COHORT ANALYSIS; MIDDLE AGED; OPIOID-RELATED DISORDERS; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; ANALGESICS, OPIOID; AUSTRALIA; CHRONIC PAIN; COHORT STUDIES; FEMALE; HUMANS; MALE; MIDDLE AGED; OPIOID-RELATED DISORDERS; RISK FACTORS; YOUNG ADULT;

EID: 84941744186     PISSN: 15262375     EISSN: 15264637     Source Type: Journal    
DOI: 10.1111/pme.12773     Document Type: Article

References (50)

1. Vos T, Flaxman AD, Naghavi M, et al. Years lived with disability (YLDs) for 1160 sequelae of 289 diseases and injuries 1990-2010: A systematic analysis for the global burden of disease study 2010. Lancet 2012;380:2163-96.
2. Blyth FM, March LM, Brnabic AJ, et al. Chronic pain in Australia: A prevalence study. Pain 2001;89:127-34.
3. Breivik H, Collett B, Ventafridda V, Cohen R, Gallacher D. Survey of chronic pain in Europe: Prevalence, impact on daily life, and treatment. Eur J Pain 2006;10:287.
4. Breivik H, Eisenberg E, O'Brien T The individual and societal burden of chronic pain in Europe: The case for strategic prioritisation and action to improve knowledge and availability of appropriate care. BMC Public Health 2013;13:1229.
5. Bloodworth D. Issues in opioid management. Am J Phys Med Rehabil 2005;84:S42-55.
6. Eisenberg E, McNicol ED, Carr DB. Efficacy of mu-opioid agonists in the treatment of evoked neuropathic pain: Systematic review of randomized controlled trials. Eur J Pain 2006;10:667-76.
7. Furlan AD, Sandoval JA, Mailis-Gagnon A, Tunks E. Opioids for chronic noncancer pain: a meta-analysis of effectiveness and side effects. CMAJ Canadian Medical Association Journal. 2006; 174:1589-94.
8. Manchikanti L, Ailinani H, Koyyalagunta D, et al. A systematic review of randomized trials of long-term opioid management for chronic non-cancer pain. Pain Phys 2011;14:91-121.
9. Noble M, Treadwell JR, Tregear SJ, Coates VH, Wiffen PJ, Akafomo C, Schoelles KM . Long-term opioid management for chronic noncancer pain. Cochrane Database of Systematic Reviews 2010, Issue 1.
10. Dhalla IA, Mamdani MM, Sivilotti MLA, et al. Prescribing of opioid analgesics and related mortality before and after the introduction of long-acting oxycodone. Can Med Assoc J 2009;181:891-6.
11. Compton WM, Volkow ND. Major increases in opioid analgesic abuse in the united states: Concerns and strategies. Drug Alcohol Depend 2006;81:103-7.
12. Roxburgh A, Bruno R, Larance B, Burns L. Prescription of opioid analgesics and related harms in Australia. Med J Aust 2011;195:280-4.
13. Leong M, Murnion B, Haber P. Examination of opioid prescribing in Australia from 1992 to 2007. Int Med J 2009;39:676-81.
14. Degenhardt L, Black E, Breen C, Bruno R. Trends in morphine prescriptions, illicit morphine use and associated harms among regular injecting drug users in Australia. Drug Alcohol Rev 2006;25:403-12.
15. Fischer B, Argento E. Prescription opioid related misuse, harms, diversion and interventions in Canada: A review. Pain Phys 2012;15:ES191-203.
16. Compton WM, Volkow ND. Abuse of prescription drugs and the risk of addiction. Drug Alcohol Depend 2006;83:S4-7.
17. Leong M, Murnion B, Haber PS. Examination of opioid prescribing in Australia from 1992 to 2007. Int Med J 2009;39:676-81.
18. Reid MC, Henderson CR Jr., Papaleontiou M, et al. Characteristics of older adults receiving opioids in primary care: Treatment duration and outcomes. Pain Med 2010;11:1063-71.
19. Lintzeris N. Commentary on Minozzi et al. (2013): Diagnosing opioid dependence in the context of long-term opioid use for chronic pain-Counting shades of grey in a black and white world. Addiction 2013;108:699-700.
20. Fishbain D, Cole B, Lewis J, Rosomoff H, Rosomoff R.What percentage of chronic nonmalignant pain patients exposed to chronic opioid analgesic therapy develop abuse/addiction and/or aberrant drug related behaviors? A structured evidence based review. Pain Med 2008;9:444-59.
21. Campbell G, Mattick R, Bruno R, et al. Cohort protocol paper: The pain and opioids in treatment (POINT) study. BMC Pharmacol Toxicol 2014;15:17.
22. Campbell G, Nielsen S, Bruno R, et al. The pain and opioids in treatment study: Characteristics of a cohort using opioids to manage chronic non-cancer pain. Pain 2015;156:231-42.
23. Therapeutic Goods Administration. Standard for the Uniform Scheduling of Medicines and Poisons (SUSMP). 2013. Available at https://www.tga.gov.au/publication/poisons-standard-susmp#susmp. Accessed December 2014.
24. Dworkin RH, Turk DC, Farrar JT, et al. Core outcome measures for chronic pain clinical trials: IMMPACT recommendations. Pain 2005;113:9-19.
25. Turk DC, Dworkin RH, Allen RR, et al. Core outcome domains for chronic pain clinical trials: IMMPACT recommendations. Pain 2003;106:337-45.
26. Cleeland C. The Brief Pain Inventory (BPI), Houston, Texas, US. 1991.
27. Nicholas MK The pain self-efficacy questionnaire: Taking pain into account. Eur J Pain 2007;11:153-63.
28. Nicholas MK, Asghari A, Blyth FM. What do the numbers mean? Normative data in chronic pain measures. Pain 2008;134:158-73.
29. Kroenke K, Spitzer RL, Williams JBW, Lowe B. The patient health questionnaire somatic, anxiety, and depressive symptom scales: A systematic review. Gen Hosp Psychiatry 2010;32:345-59.
30. Kroenke K, Spitzer R, Williams JBW. The PHQ-9: Validity of a brief depression severity measure. J Gen Intern Med 2001;16:606-13.
31. Spitzer RL, Kroenke K, Williams JBW, Lowe B. A brief measure for assessing generalized anxiety disorder: The GAD-7. Arch Intern Med 2006;166:1092-7.
32. Andrews G, Hall W, Teesson M, Henderson S. The Mental Health of Australians: National Survey of Mental Health and Wellbeing. Canberra: Commonwealth Department of Health and Aged Care; 1999.
33. Prins A, Ouimette P, Kimerling R, et al. The primary care PTSD screen (PC-PTSD): development and operating characteristics. Prim Care Psychiatry 2004;9:9-14.
34. World Health Organization. Composite International Diagnostic Interview, Version 3.0. Geneva: World Health Organization; 2001.
35. Sullivan M, Von Korff M, Banta-Green C, Merrill J, Saunders K. Problems and Concerns of Patients Receiving Chronic Opioid Therapy for Chronic Non-Cancer Pain 2010;149:345-353.
36. Larance B, Bruno R, Lintzeris N, et al. Development of the opioid related behaviours in treatment (ORBIT) scale. In preparation.
37. Nielsen S, Degenhardt L, Hoban B, Gisev N. Comparing opioids: A guide to estimating oral morphine equivalents (OME) in research. NDARC Technical Report No. 329. Sydney: National Drug and Alcohol Research Centre, UNSW Australia, 2014.
38. Manchikanti L, Abdi S, Atluri S, et al. American Society of Interventional Pain Physicians (ASIPP) guidelines for responsible opioid prescribing in chronic non-cancer pain: Part 2-Guidance. Pain Phys 2012;15:S67-116.
39. Zedler B, Xie L, Wang L, et al. Risk factors for serious prescription opioid-related toxicity or overdose among veterans health administration patients. Pain Med 2014;15:1911-29.
40. Minozzi S, Amato L, Davoli M. Development of dependence following treatment with opioid analgesics for pain relief: A systematic review. Addiction 2013;108:688-98.
41. Clarke H, Soneji N, Ko DT, Yun L, Wijeysundera DN. Rates and risk factors for prolonged opioid use after major surgery: Population based cohort study. BMJ (Clin Res Ed) 2014;348:g1251.
42. Cochran BN, Flentje A, Heck NC, et al. Factors predicting development of opioid use disorders among individuals who receive an initial opioid prescription: mathematical modeling using a database of commercially-insured individuals. Drug Alcohol Depend 2014;138:202-8.
43. Rogers KD, Kemp A, McLachlan AJ, Blyth F. Adverse selection? A multi-dimensional profile of people dispensed opioid analgesics for persistent non-cancer pain. PloS One 2013;8:e80095.
44. Sullivan MD. Who gets high-dose opioid therapy for chronic non-cancer pain? Pain 2010;151:567-8.
45. Webster LR, Webster RM. Predicting aberrant behaviors in opioid-treated patients: Preliminary validation of the opioid risk tool. Pain Med 2005;6:432-42.
46. Passik SD, Kirsh KL. The interface between pain and drug abuse and the evolution of strategies to optimize pain management while minimizing drug abuse. Exp Clin Psychopharmacol 2008;16:400-4.
47. Gourlay DL, Heit HA, Almahrezi A. Universal precautions in pain medicine: A rational approach to the treatment of chronic pain. Pain Med 2005;6:107-12.
48. Royal Australian College of Physicians. Prescription Opioid Policy: Improving Management of Chronic Non-Malignant Pain and Prevention of Problems Associated with Prescription Opioid Use. Sydney: Royal Australasian College of Physicians, Sydney, New South Wales, Australia, 2009.
49. Darke S. Self-report among injecting drug users: A review. Drug Alcohol Depend 1998;51:253-63.
50. Svendsen K, Borchgrevink P, Fredheim O, et al. Choosing the unit of measurement counts: The use of oral morphine equivalents in studies of opioid consumption is a useful addition to defined daily doses. Palliat Med 2011;25:725-32.